ALPMF (Astellas Pharma) PensionAndRetirementBenefit : $153 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma PensionAndRetirementBenefit?

Astellas Pharma's PensionAndRetirementBenefit for the quarter that ended in Mar. 2025 was $153 Mil.

Astellas Pharma's quarterly PensionAndRetirementBenefit declined from Sep. 2024 ($166 Mil) to Dec. 2024 ($156 Mil) and declined from Dec. 2024 ($156 Mil) to Mar. 2025 ($153 Mil).

Astellas Pharma's annual PensionAndRetirementBenefit declined from Mar. 2023 ($186 Mil) to Mar. 2024 ($165 Mil) and declined from Mar. 2024 ($165 Mil) to Mar. 2025 ($153 Mil).

Astellas Pharma PensionAndRetirementBenefit Historical Data

The historical data trend for Astellas Pharma's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma PensionAndRetirementBenefit Chart

Astellas Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

PensionAndRetirementBenefit

Get a 7-Day Free Trial

358.62

313.94

185.67

164.69

152.60

Astellas Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
PensionAndRetirementBenefit	Get a 7-Day Free Trial															164.69	160.76	166.06	155.82	152.60

Astellas Pharma PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.